Mutations in DNA damage repair genes associated with response to cisplatin in bladder cancer: Prospective validation from SWOG S1314 trial
An analysis of pre-treatment tumor specimens from 105 patients with localized muscle-invasive bladder cancer found that the presence of a mutation in any one of three genes, all known to be involved in DNA damage repair, was associated with complete pathologic response to cisplatin-based neoadjuvant